{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-24-000012","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.835183+00:00","generated_at":"2026-06-04T23:51:34.567391+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Caribou Biosciences reports FY 2023 net loss $102.1M, cash $372.4M; clinical updates","bullets":["Net loss $102.1M in FY 2023 vs $99.4M in FY 2022; R&D expenses rose to $112.1M.","Cash, equivalents, and marketable securities $372.4M at Dec 31, 2023, up from $317.0M; expected to fund operations into Q1 2026.","CB-010: 30th patient dosed in ANTLER dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024.","CB-012: First patient dosed in AMpLify Phase 1 trial for r/r AML.","CB-020 preclinical anti-ROR1 CAR-NK program paused; CB-011 enrollment continues at dose level 3."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-24-000012","json":"https://secwatch.observer/filing/0001619856-24-000012.json","markdown":"https://secwatch.observer/filing/0001619856-24-000012.md","text":"https://secwatch.observer/filing/0001619856-24-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000012/0001619856-24-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000012/crbu-20240311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:51:34.567391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df4f3ede3eaa82e4469d9bb21968778e5777999d","claim":"Caribou Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On March 11, 2024, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2023 and providing a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000012/0001619856-24-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}